idarubicin has been researched along with Di Guglielmo Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arioka, Y; Funato, T; Hara, T; Kawasoe, M; Markey, SP; Matsunami, H; Moriwaki, H; Okawa, K; Saito, K; Takeda, M; Takemura, M; Tsurumi, H; Yamamoto, Y | 1 |
| Creutzig, U; Dworzak, MN; Reinhardt, D; Ritter, J; Schellong, G; Zimmermann, M | 1 |
| Bandieri, E; Forghieri, F; Luppi, M; Maccaferri, M; Morselli, M; Potenza, L; Torelli, G; Volzone, F | 1 |
| Hara, T; Kitagawa, J; Moriwaki, H; Oyama, M; Tsurumi, H | 1 |
| Gould, PA; Hengel, CL; Kaye, DM; Russell, PA | 1 |
| Huerta, F; Reynoso, EE | 1 |
| Aul, C; Burk, M; Gogolin, F; Heyll, A; Meckenstock, G; Runde, V; Söhngen, D; Winkelmann, M; Wolf, HH; Zahner, J | 1 |
| Dubru, F; Fiallo, M; Garnier-Suillerot, A; Hesschenbrouck, J; Mankhetkorn, S | 1 |
| Garnier-Suillerot, A; Pereira, E; Tarasiuk, J | 1 |
| Ahn, YK; Cho, JG; Chung, IJ; Kim, HJ; Lee, JJ; Park, MR; Shin, DH | 1 |
1 review(s) available for idarubicin and Di Guglielmo Disease
| Article | Year |
|---|---|
Development of a curative treatment within the AML-BFM studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Germany; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Methotrexate; Multicenter Studies as Topic; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thioguanine; Vincristine | 2013 |
1 trial(s) available for idarubicin and Di Guglielmo Disease
| Article | Year |
|---|---|
Results of conventional-dose cytosine arabinoside and idarubicin in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Survival Analysis | 1994 |
8 other study(ies) available for idarubicin and Di Guglielmo Disease
| Article | Year |
|---|---|
Acquired resistance of leukemic cells to AraC is associated with the upregulation of aldehyde dehydrogenase 1 family member A2.
Topics: Aldehyde Dehydrogenase 1 Family; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Enzyme Induction; Gene Expression Regulation, Leukemic; Humans; Idarubicin; K562 Cells; Leukemia; Leukemia, Erythroblastic, Acute; Neoplasm Proteins; Prodrugs; Retinal Dehydrogenase; RNA Interference; RNA, Small Interfering; Transfection; Up-Regulation | 2013 |
Persistent hiccups as an adverse event to FLAG-IDA regimen for leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Filgrastim; Granulocyte Colony-Stimulating Factor; Hiccup; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Vidarabine | 2009 |
Pure erythroid leukemia with hemophagocytosis.
Topics: Antineoplastic Agents; Bone Marrow; Cytarabine; Fatal Outcome; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Lymphohistiocytosis, Hemophagocytic; Male; Methylprednisolone; Middle Aged | 2009 |
Subacute anthracycline cardiotoxicity.
Topics: Adult; Antibiotics, Antineoplastic; Cardiomyopathies; Cytarabine; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Male; Ultrasonography | 2006 |
Acute leukemia and pregnancy--fatal fetal outcome after exposure to idarubicin during the second trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fetal Death; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Remission Induction | 1994 |
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cell Membrane Permeability; Cell Nucleus; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Leukemia, Erythroblastic, Acute; Microbial Sensitivity Tests; Tumor Cells, Cultured | 1996 |
Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Doxorubicin; Drug Resistance, Multiple; Humans; Hydrogen-Ion Concentration; Idarubicin; Kinetics; Leukemia, Erythroblastic, Acute; Tumor Cells, Cultured; Vinblastine; Vinca Alkaloids; Vincristine; Vindesine; Vinorelbine | 1998 |
Life-threatening paroxysmal supraventricular tachycardia developed during granulocyte transfusion therapy for neutropenia-related infection.
Topics: Adult; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Citrates; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Idarubicin; Infections; Leukapheresis; Leukemia, Erythroblastic, Acute; Leukocyte Transfusion; Male; Neutropenia; Sodium Citrate; Tachycardia, Supraventricular | 2000 |